Artificial intelligence (AI)-driven commercial optimisation platform provider Verix has purchased for an undisclosed sum, boosting its life science AI capabilities. is a group of AI specialists that helps enterprises improve their processes through AI and machine learning.

The company will be merged with Verix’s AI lab, and co-founder and CEO Shahar Cohen will become Verix’s CTO.

The deal enables Verix to further improve its capacities to use AI to advance the brand growth of life science companies.

Pharmaceutical firms usually depend upon consulting analytical services for marketing and sales decisions related to their strategy and execution. This is a time-consuming and costly process.

Verix states that it leverages AI to provide more in-depth, precise data on the market more quickly and at a lower cost.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company also uses anonymised drug prescription data from healthcare professionals (HCPs) and multiple data sets such as lab data, digital marketing information and demographics to help pharma firms optimise the processes related to their business.

Using these data, pharma firms can also ensure that the right medicines will be available to the right patients at the right time.

Verix CEO Doron Aspitz stated: “In our time working with, we were consistently impressed with their AI capabilities and innovative approach to solving customer challenges.

“As we continue to grow, serving more and more customers, we understand the strategic value of continuing to build out category-leading AI capabilities, which are embedded in Tovana, our opportunity engine platform.

“Adding the team to Verix was a natural decision for us and we are excited about what our new capabilities will enable us to deliver to our customers and partners around the world.”